SCHEMBL3321999

SCHEMBL3321999

C[C@@H]1CN(c2ccc(NC(=O)[C@H]3CC[C@@H](Oc4cc(C(F)(F)F)ccn4)CC3)cc2)C[C@H](C)O1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.51
KDR P35968 6/20 0.51
HCRTR1 O43613 2/20 0.46
HCRTR2 O43614 2/20 0.46
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.41
TRPV1 Q8NER1 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GSK3B P49841 1/20 0.41
LRRK2 Q5S007 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3346715 0.87 HCRTR1 (0.43) BRAFKDRHCRTR1HCRTR2KMT2A
SCHEMBL3347288 0.81 BRAF (0.44) BRAFKDRMEN1KMT2AKDM4E
SCHEMBL3333489 0.78 KDR (0.49) BRAFKDRMEN1KMT2ALMNA
SCHEMBL10190932 0.78 MAPT (0.45) HCRTR1HCRTR2USP2MAPTALDH1A1
SCHEMBL10191574 0.74 GNRHR (0.39) BRAFKDRHCRTR1HCRTR2MEN1
SCHEMBL3337931 0.73 ALDH1A1 (0.55) KMT2ATSHRSMN1; SMN2MAPTALDH1A1
SCHEMBL13370597 0.73 MAPT (0.58) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL13716211 0.73 MAPT (0.58) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL13973092 0.72 MAPT (0.56) MEN1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL3367450 0.71 MAPT (0.44) MEN1KMT2AKDM4EHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653125-B2 Cyclohexane derivative having NPY Y5 receptor antagonism SHIONOGI CO., LTD. (JP) 2014-02-18 US disclosed
US-20120004227-A1 CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM SHIONOGI & CO., LTD. (JP) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004227-A1 CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM NPY5R, NPY1R, NPY2R BRAF 3058/4885KDR 895/4885HCRTR1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.